- Home
- FIVN vs IDYA Comparison
FIVN vs IDYA Comparison
Compare FIVN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- IDYA
- Stock Information
- Founded
- FIVN 2001
- IDYA 2015
- Country
- FIVN United States
- IDYA United States
- Employees
- FIVN N/A
- IDYA N/A
- Industry
- FIVN EDP Services
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- FIVN Technology
- IDYA Health Care
- Exchange
- FIVN Nasdaq
- IDYA Nasdaq
- Market Cap
- FIVN 2.1B
- IDYA 1.9B
- IPO Year
- FIVN 2014
- IDYA 2019
- Fundamental
- Price
- FIVN $28.84
- IDYA $24.50
- Analyst Decision
- FIVN Buy
- IDYA Strong Buy
- Analyst Count
- FIVN 21
- IDYA 13
- Target Price
- FIVN $42.90
- IDYA $50.82
- AVG Volume (30 Days)
- FIVN 2.4M
- IDYA 999.0K
- Earning Date
- FIVN 07-31-2025
- IDYA 08-05-2025
- Dividend Yield
- FIVN N/A
- IDYA N/A
- EPS Growth
- FIVN N/A
- IDYA N/A
- EPS
- FIVN N/A
- IDYA N/A
- Revenue
- FIVN $1,074,633,000.00
- IDYA $7,000,000.00
- Revenue This Year
- FIVN $11.81
- IDYA $115.83
- Revenue Next Year
- FIVN $9.79
- IDYA $252.50
- P/E Ratio
- FIVN N/A
- IDYA N/A
- Revenue Growth
- FIVN 14.44
- IDYA N/A
- 52 Week Low
- FIVN $21.04
- IDYA $13.45
- 52 Week High
- FIVN $49.90
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- FIVN 58.95
- IDYA 65.66
- Support Level
- FIVN $25.01
- IDYA $21.33
- Resistance Level
- FIVN $29.24
- IDYA $25.54
- Average True Range (ATR)
- FIVN 1.16
- IDYA 1.00
- MACD
- FIVN 0.23
- IDYA 0.21
- Stochastic Oscillator
- FIVN 81.49
- IDYA 75.93
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.